Citations

Clear

11 citation(s) found for "Chen, Chih-Yi".

Portal Vein Thrombosis in Pediatric Liver Transplantation With Technical Variant Grafts: An International Multicenter Analysis of Risk and Prognostic Factors
Raptis, Dimitri A., Gunasekaran, Vasanthakumar , Rammohan, Ashwin, Sakamoto, Seisuke, Uchida, Hajime, Beekum, Cornelius J. van, Krendl, F. J., Chen, Itsuko Chih-Yi, Domenick, Bryanna , Kow, Alfred, Soejima, Yuji, Furuya, Katryn N. , Mazariegos, George V., Dunn, Stephen, Olthoff, Kim, Rand, Elizabeth B. , Chen, C L, Balci, Deniz, Nadalin, Silvio, Schneeberger, Stefan, Sudan, Debra L., Schmelzle, Moritz, Herden, Uta , Fischer, L, Sayed, Blayne A., Ng, Vicky L, Kasahara, Mureo, Rela, Mohamed, Broering, Dieter C., Xia, Qiang, Clavien, P A, Li, Zhihao, Sudan, Debra L. , Li, Zhihao , Sayed, Blayne A , Sudan, Debra L , Li, Zhihao , Wang, Kaihang , Madadi‐Sanjani, Omid , Y, Liu , Raptis, Dimitri , Rammohan, Ashwin , Sakamoto, Seisuko , Uchida, Hajime , Kaliciński, Piotr , Goldaracena, Nicolás , Beekum, Cornelius J. van , Krendl, Felix Julius , Chen, Itsuko Chih-Yi, Kow, Alfred Wei Chieh , Soejima, Yuji , Mazariegos, George , Mali, Vidyadhar Padmakar , Leipnitz, Ian , Balci, Deniz , Kirimker, Elvan Onur , Nadalin, Silvio , Schneeberger, Stefan , Schmelzle, Moritz , Sayed, Blayne A. , Kowalewski, Grzegorz , Kasahara, Mureo , Rela, Mohamed , Bröering, Dieter C. , Xia, Qiang

Mayo Clinic

Transplantation | June 9, 2026 | Volume: 110 | Issue: 8 | Pages: e1695-e1704

10.1097/tp.0000000000005777 | PMID 42263010 Get It

Background. The adoption of technical variant grafts has expanded the donor pool for pediatric liver transplantation, but it also poses a risk of portal vein thrombosis (PVT). This study evaluated risk and prognostic factors of PVT in children undergoing liver transplantation with technical variant grafts. Methods. A total of 3137 pediatric patients from 19 centers were included: 470 received split/reduced deceased donor grafts and 2667 received living donor grafts. Multivariable logistic regression was used to identify risk factors, whereas time-dependent Cox models were used to assess the impact on survival. Results. PVT occurred in 102 patients (3.3%) and was associated with increased mortality (adjusted hazard ratio, 2.86; 95% confidence interval [CI], 1.13-7.25; P = 0.027) and graft loss (adjusted hazard ratio, 9.97; 95% CI, 4.90-20.3; P < 0.001). Risk factors included younger age, lower weight, higher Pediatric End-Stage Liver Disease score, longer cold ischemia and operation times, higher graft-to-recipient weight ratio, increased red blood cell transfusions, and biliary atresia. After adjusting for center, lower weight (odds ratio, 0.84 per kg; 95% CI, 0.71-1.00; P = 0.047) and biliary atresia (odds ratio, 2.34; 95% CI, 1.10-5.00; P = 0.027) remained predictors. Five-year patient (88.4% versus 93.1%) and graft survival (82.7% versus 96.3%) were significantly inferior in patients with PVT. Conclusions. Low-weight children with biliary atresia constituted a high-risk group, highlighting the necessity for early detection and management.
Early graft failure after adult living donor liver transplantation: A multicenter risk analysis and development of the early allograft failure in living donor liver transplantation (EAGLE-LDLT) model
Li, Zhihao, Centonze, Leonardo , Raptis, Dimitri , Marquez, Kris Ann Hervera , Rammohan, Ashwin, Gunasekaran, Vasanthakumar , Hong, Suyoung , Chen, I Lun, KIM, Jongman , Hsu, Shih-Chao , Akamatsu, Nobuhisa, Shaked, Oren, Genedy, Lara, Dutkowski, Philipp , Nadalin, Silvio, Boehnert, Markus U, Mathur, Abhishek, Emond, J., Testa, Giuliano, Olthoff, Kim, Taner, Timucin, Wong, Tiffany CL, Hasegawa, Kiyoshi, Balci, D., Cattral, Mark, Sapisochin, G., Selzner, Nazia, Jeng, Long-Bin, Chen, Chao-Long, Suh, Kyung-Suk, Rela, Mohamed, Broering, Dieter, Clavien, Pierre-Alain, Kim, Jong Man , Raptis, Dimitri Aristotle , Li, Zhihao , Hong, Su young , Chen, I. , Centonze, Leonardo , Li, Zhihao , Rammohan, Ashwin , Chen, Itsuko Chih-Yi , Kirimker, Elvan Onur , Akamatsu, Nobuhisa , Shaked, Oren , Finotti, Michele , Yeow, Marcus , Nadalin, Silvio , Boehnert, Markus U , Polak, Wojciech G , Bonney, Glenn K , Samstein, Benjamin , Emond, Jean C , Testa, Giuliano , Olthoff, Kim M , Heimbach, Julie K , Taner, Timucin , Wong, Tiffany C L , Balci, Deniz , Cattral, Mark , Sapisochin, Gonzalo , Selzner, Nazia , Jeng, Long-Bin , Joh, Jae-Won , Chen, Chao-Long , Suh, Kyung-Suk , Di Sandro, Stefano , Rela, Mohamed , Broering, Dieter , Clavien, Pierre-Alain , Akamatsu, Nobuhisa , Shaked, Oren , Boehnert, Markus , Polak, Wojciech G. , Mathur, Abhishek , Samstein, Benjamin , Emond, Jean C. , Testa, Giuliano , Heimbach, Julie K. , Taner, Timuçin , Wong, Tiffany , Hasegawa, Kiyoshi , Cattral, Mark S. , Sapisochín, Gonzalo , Selzner, Nazia , Joh, Jae‐Won , Rela, Mohamed , Bröering, Dieter C. , Clavien, Pierre‐Alain

Mayo Clinic

Liver Transplantation | January 21, 2026 | Volume: 32 | Issue: 7 | Pages: 1027-1039

10.1097/lvt.0000000000000816 | PMID 41564353 Get It

Early allograft failure (EAF) after living donor liver transplantation (LDLT) remains a clinical challenge. Existing prediction models developed for deceased donor transplantation poorly apply to LDLT due to distinct surgical and physiological factors. This study identifies clinical determinants of EAF and develops an LDLT-specific prediction model. We conducted a multicenter retrospective cohort study from 17 high-volume LDLT centers (January 2016–December 2020) with external validation at a tertiary center in Saudi Arabia (January 2015–December 2022). The primary outcome was EAF (graft loss or patient death ≤90 d). Multivariable mixed-effects logistic regression identified preoperative/intraoperative risk factors. The EAGLE-LDLT model was constructed using postoperative laboratory values. Performance was compared against established models (EAD, MEAF, A2ALL) using ROC analysis and decision curve analysis. The development cohort included 2944 adult LDLT recipients (67.7% male; median age 55 y; median MELD 14) with a 5.5% EAF rate. External validation included 1020 recipients (median MELD 21, 6.7% EAF). Independent risk factors for EAF were MELD (OR 1.06, 95% CI 1.04–1.08), donor BMI (OR 1.05, 95% CI 1.00–1.10), portal vein thrombosis (OR 1.73, 95% CI 1.13–2.63), and hepaticojejunostomy (OR 1.58, 95% CI 1.06–2.36). The EAGLE-LDLT model incorporating peak ALT (>468 U/L), peak INR (>1.9), and bilirubin (>3.5 mg/dL) and INR (>1.3) at POD7, demonstrated superior discrimination (AUC=0.81) compared with MEAF (AUC=0.77, p =0.004), EAD (AUC=0.67, p <0.001), and A2ALL (AUC=0.65, p <0.001). EAGLE-LDLT achieved balanced sensitivity (75.0%) and specificity (73.7%), effectively stratifying patients into high-risk (15% of patients; 40.4% EAF incidence) and low-risk groups. Preoperative and intraoperative clinical factors predict EAF in LDLT. The EAGLE-LDLT model accurately identifies LDLT recipients at the highest risk for EAF postoperatively.
A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked
Wei, Zhao , Zhang, Tongwu , Hua, Xing , Hoang, Phuc H. , Miraftab, Mona , Saha, Monjoy , McElderry, John, Sang, Jian , Lee, Olivia W. , Hartman, Caleb , Sharma, Sunandini , Colón-Matos, Frank J. , Anyaso‐Samuel, Samuel , Hutchinson, Amy , Hicks, Belynda , Rosenbaum, Jennifer, Zhong, Xiaoming , Yang, Yang , Leung, Kin Chung, Wong, Maria Pik , Mańczuk, Marta , Shangina, Oxana , Заридзе, Давид , Milosavljević, Saša , Ognjanovic, Simona , Savić, Milan , Gaborieau, Valérie , Brennan, Paul , Edell, Eric S. , Más, Luís , Chen, Chih‐Yi , Chang, I‐Shou , Hsiung, Chao A. , Liu, Geoffrey , Santamaría, Juan Miguel , Mutreja, Karun , Rothman, Nathaniel , Leduc, Charles , Sholl, Lynette M. , Lan, Qing , Yang, Lixing , Shi, Jianxin , Landi, Maria Teresa , Zhao, Wei , McElderry, John P , Khandekar, Azhar , Sharma, Sunandini , Colón-Matos, Frank J , Anyaso-Samuel, Samuel , Wang, Difei , Jones, Kristine , Hutchinson, Amy , Hicks, Belynda , Rosenbaum, Jennifer , Zhong, Xiaoming , Yang, Yang , Pesatori, Angela C , Consonni, Dario , Christiani, David C. , Leung, Kin Chung , Wong, Maria Pik , Manczuk, Marta , Lissowska, Jolanta , Świątkowska, Beata , Mukeria, Anush , Shangina, Oxana , Zaridze, David , Holcatova, Ivana , Mates, Dana , Milosavljevic, Sasa , Ognjanovic, Simona , Savic, Milan , Kontic, Milica , Gaborieau, Valerie , Brennan, Paul , Arrieta, Oscar , Bossé, Yohan , Schabath, Matthew B , Hofman, Paul , Mas, Luis , Yendamuri, Sai S , Chen, Chih-Yi , Chang, I-Shou , Hsiung, Chao Agnes , Liu, Geoffrey , Martinez Santamaría, Jacobo , Gould Rothberg, Bonnie E , Mutreja, Karun , Lawrence, Scott M. , Rothman, Nathaniel , Alexandrov, Ludmil B , Leduc, Charles , Baine, Marina K , Joubert, Philippe , Sholl, Lynette , Travis, William D , Homer, Robert , Lan, Qing , Chanock, Stephen Jacob , Yang, Lixing , Yang, Soo-Ryum , Shi, Jianxin , Landi, Maria T , Lissowska, Jolanta , Świątkowska, Beata , Holcátová, Ivana , Mateș, Dana , Arrieta, Óscar , Bossé, Yohan , Schabath, Matthew B. , Alexandrov, Ludmil B. , Travis, William D. , Homer, Robert

Mayo Clinic

Cancer Discovery | October 30, 2025 | Volume: 16 | Issue: 3 | Pages: 460-477

10.1158/2159-8290.cd-25-0581 | PMID 41165571 Get It

Abstract Understanding tumor cell dynamics can improve prognosis and treatment but remains limited for lung adenocarcinoma in people who have never smoked (NS-LUAD). With RNA sequencing data from 684 NS-LUAD cases and validation in an independent dataset, we identified three subtypes with distinct phenotypic traits and cell compositions. Additional genomic and histologic data further characterized the subtypes. “Steady,” marked by low proliferation, high alveolar cell fraction, moderate-to-well differentiation, and fewer driver gene alterations, is linked to prolonged survival and low immune evasion. “Proliferative” shows high proliferation markers, TP53 mutations, and gene fusions. “Chaotic,” with high epithelial-to-mesenchymal transition markers, has the worst prognosis, even within stage I tumors. Lacking known molecular or histologic characteristics, this aggressive subtype is solely identified by transcriptomic data. A 60-gene signature recapitulates the classification and predicts survival even within subgroups based on tumor stage or known genomic features, emphasizing its potential for improving early-stage NS-LUAD prognostication in clinical settings. Significance: The transcriptome of 684 NS-LUAD identifies three subtypes with different cellular dynamics and genomic and morphologic features. A 60-gene signature accurately stratifies subjects for mortality risk, even in stage I, offering a potential clinically applicable tool for treatment decision-making in patients with NS-LUAD. See related commentary by Azizi et al., p. 423
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers
Blechter, Batel , Wang, Xiaoyu , Karsonaki, Christiana, Shi, Jianxin , Shiraishi, Kouya , Choi, Jiyeon , Matsuo, Keitaro , Chen, Tzu‐Yu , Kim, Young Tae , Choudhury, Parichoy Pal , Williams, Jacob , Landi, Maria Teresa , Yin, Zhihua , Zhou, Baosen , Seow, Wei Jie , Song, Lei , Chang, I‐Shou , Chien, Li-Hsin , Wong, Maria Pik , Richardson, Brian Douglas , Li, Shilan , Breeze, Charles E. , Bassig, Bryan A. , Sm, Jason Yy Wong, Chung, Lap Ping, Zhang, Xu‐Chao , Caporaso, Neil E. , Chang, Jiang , Ho, Jcm , Momozawa, Yukihide , Kobayashi, Masashi , Okubo, Kenichi , Honda, Takayuki , Kunitoh, Hideo , Watanabe, Shun-ichi, Hamamoto, Ryuji , Goto, Kōichi , Minamiya, Yoshihiro, Wakai, Kenji , Murakami, Yoshinori , Shimizu, Kimihiro , Suzuki, Hiroyuki , Ohtaki, Yoichi , Tanaka, Kazumi , Wu, Tangchun , Wei, Fusheng, Kim, Yeul Hong , Chang, Gee-Chen , Chen, Kuan‐Yu, Chen, Yuh-Min, Park, Jae Yong , Kweon, Sun-Seog, Gao, Yu‐Tang , Schwartz, Ann G. , Gorlov, Ivan , Wu, Xifeng , Yang, Ping , Lam, Stephen , Bojesen, Stig E. , Ji, Bu‐Tian , Wichmann, H. E., Christiani, D.C., Brennan, Paul , McKay, James , Field, John K. , Shete, Sanjay , Marchand, Loı̈c Le, Liu, Geoffrey , Andrew, Angeline S. , Zienolddiny-Narui, Shan, Grankvist, Kjell , Taylor, Fiona, Aldrich, Melinda C. , Jeon, Hyo‐Sung, Hu, Zhibin , Burdett, Laura, Yeager, Meredith, Hutchinson, Amy , Hicks, Belynda , Liu, Jia , Berndt, Sonja I, Wu, Wei , Wang, Junwen , Choi, Jin Eun , Park, Kyong Hwa , Sung, Sook Whan , Tan, Wen , Sihoe, Alan , Choi, Yi Young, Hung, Hsiao-Han , Vermeulen, Roel , Wu, Junjie , Tsai, Fang-Yu , Chan, John K. C., Li, Jihua , Lin, Hsien-Chih, Liu, Jie , Sawada, Norie , Yamaji, Taiki , Wyatt, Kathleen , Qi, T. Y., Li, Xuelian , Ren, Yangwu , Chao, Ann, Zhu, Junjie , Chen, Chih‐Yi , ScD, Chien-Jen Chen, Stevens, Victoria L. , Fraumeni, Joseph F., Lin, Kuang , Walters, Robin G., Chen, Zhengming, Chatterjee, Nilanjan , Gorlova, Olga Y. , Hsiung, Chao A. , Chanock, Stephen J, Rothman, Nathaniel , Kohno, Takashi , Lan, Qing, Kartsonaki, Christiana , Liu, Geoffrey , Field, John K , Matsuo, Keitaro , Wang, Junwen , Bojesen, Stig E , Grankvist, Kjell , Chen, Chih-Yi , Dai, Juncheng , Hung, Rayjean J. , Chen, Kexin , Shu, Xiao-Ou , Choudhury, Parichoy Pal , Lin, Dongxin , Zheng, Wei , Wang, Jiucun , Hu, Wei , Cai, Qiuyin , Hong, Yun‐Chul , Kim, Hee Nam , Wu, Yi-Long Lung Cancer , Richardson, Brian Douglas , Zhang, Tongwu , Wang, Zhaoming , Kim, Jin Hee , Albanes, Demetrius , Shin, Min‐Ho , Chung, Lap-Ping, Yang, Yang , Zheng, Hong , Dai, Hong , Yatabe, Yasushi , Kim, Young‐Chul , Daigo, Yataro , Kamatani, Yoichiro , Kobayashi, Masashi , Hosgood, Howard Dean , WATANABE, Shun-ichi J. , Miyagi, Yohei , Matsumoto, Shingo , Horinouchi, Hidehito , Tsuboi, Masahiro , Takahashi, Atsushi , Goto, Akiteru , Hara, Megumi , Nishida, Yuichiro , Takeuchi, Kenji , Matsuda, Koichi , Murakami, Yoshinori, Suzuki, Hiroyuki , Saito, Motonobu , Machiela, Mitchell J. , Oh, In‐Jae , Lee, Victor , Su, Wu‐Chou , Seow, Adeline , Kweon, Sun-Seog , Liu, Jianjun , Houlston, Richard S. , Tardón, Adonina , Chen, Chu, Johansson, Mattias , Risch, Angela , Bickeböller, Heike , Rennert, Gad , Arnold, Susanne M. , Davies, Michael P.A. , Kiemeney, Lambertus A. , Cox, Angela , Yuan, Jian-Min , Lazarus, Philip J. , Schabath, Matthew B. , Jiang, Shih Sheng , Chen, Chung–Hsing , Hsiao, Chin‐Fu , Yeager, Meredith , Liu, Jia , Berndt, Sonja I. , Li, Yuqing , Kang, Chang Hyun , Wang, Wen‐Chang , Xu, Jun, Guan, Peng , Yu, Chong‐Jen , Yang, Gong , Park, In Kyu , Cheng, Iona C. , Song, Bao, Wyatt, Kathleen , Ma, Hongxia , Zhu, Meng , Wang, Yifan , Qi, Tianchen, Iwasaki, Motoki , Wu, Guoping , Yang, Pan‐Chyr , Walters, Robin G. , Chatterjee, Nilanjan , Amos, Christopher I. , Shen, Hongbing , Rothman, Nathaniel , Lan, Qing , Zhang, Haoyu

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 18, 2025 | Volume: 118 | Issue: 2 | Pages: 231-249

10.1093/jnci/djaf272 | PMID 41032288 Get It

Abstract Background Lung adenocarcinoma in never-smokers is a major public health burden, especially among East Asian women. Polygenic risk scores (PRSs) are promising for risk stratification but are primarily developed in European-ancestry populations. We aimed to develop and validate single- and multi-ancestry PRSs for East Asian never-smokers to improve lung adenocarcinoma risk prediction. Methods PRSs were developed using genome-wide association study summary statistics from East Asian (8002 cases; 20 782 controls) and European (2058 cases; 5575 controls) populations. Single-ancestry models included a PRS with 25 single nucleotide variants (PRS-25), PRS clumping and thresholding (CT), and LDpred2; multi-ancestry models included LDpred2 plus European PRS-128, PRS-CSx, and clumping and thresholding, super learning, empirical Bayes (CT-SLEB). Performance was evaluated in independent East Asian data from the Female Lung Cancer Consortium and externally validated in the Nanjing Lung Cancer Cohort. We assessed predictive accuracy via area under the curve operating procedure (AUC), with 10-year and (ages 30-80 years) absolute risks estimates. Results The best multi-ancestry PRS, using East Asian and European data via CT-SLEB, outperformed the best East Asian-only (LDpred2; AUC = 0.629, 95% confidence interval [CI] = 0.618 to 0.641), achieving an AUC of 0.640 (95% CI = 0.629 to 0.653) and odds ratio of 1.71 (95% CI = 1.61 to 1.82) per standard deviation increase. Nanjing Lung Cancer Cohort validation confirmed robust performance (AUC = 0.649, 95% CI = 0.623 to 0.676). The top 20% PRS group had a 3.92-fold higher lung adenocarcinoma risk than the bottom 20%. Further, the top 5% PRS group reached a 6.69% lifetime absolute risk. Notably, this group reached the average population 10-year lung adenocarcinoma risk at age 50 years (0.42%) by age 41 years, 9 years earlier. Conclusions Multi-ancestry PRS approaches enhance lung adenocarcinoma risk stratification in East Asian never-smokers, with consistent external validation, suggesting future clinical utility.
Deciphering lung adenocarcinoma evolution and the role of LINE-1 retrotransposition
Yin, Jinhu , Leduc, Charles , Sholl, Lynette M. , McElderry, John, Hartman, Caleb , Rosenbaum, Jennifer, Colón-Matos, Frank J. , Miraftab, Mona , Caporaso, Neil E. , Wong, Maria Pik , Leung, Kin Chung, Hsiung, Chao A. , Chen, Chih-Yi, Edell, Eric S. , Santamaría, Jacobo Martínez, Mańczuk, Marta , Mukeria, Anush, Shangina, Oxana , Заридзе, Давид , Mates, Dana, Milosavljević, Saša , Savić, Milan , Gaborieau, Valérie , Hofman, Paul L. , Yang, Lixing , Shi, Jianxin , Brown, Kevin M. , Rothman, Nathaniel , Choi, Jiyeon , Lan, Qing , Wedge, David C. , Landi, Maria Teresa , Chen, Chih‐Yi , Manczuk, Marta , Chen, Chih-Yi , Leduc, Charles , Zhang, Tongwu , Zhao, Wei , Wirth, Christopher, Díaz‐Gay, Marcos , Cecati, Monia , Marchegiani, Francesca , Hoang, Phuc H. , Baine, Marina K , Travis, William D. , Joubert, Philippe , Sang, Jian , Klein, Alyssa , Khandekar, Azhar , Saha, Monjoy , Lee, Olivia W. , Jones, Kristine , Santamaría, Jacobo Martínez, Schabath, Matthew B. , Yendamuri, Sai S , Lissowska, Jolanta , Świątkowska, Beata , Holcátová, Ivana , Milosavljevic, Sasa , Bossé, Yohan , Gould Rothberg, Bonnie E , Christiani, David C. , Brennan, Paul Martin , Liu, Geoffrey , Hofman, Paul , Homer, Robert , Yang, Soo-Ryum , Pesatori, Angela C , Consonni, Dario , Zhu, Bin , Chanock, Stephen Jacob , Alexandrov, Ludmil B. , Cardelli, Maurizio , Nowak, Martin A.

Mayo Clinic

No container title available | March 16, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.03.14.643063 | PMID 40161734 Get It

ABSTRACT Understanding lung cancer evolution can identify tools for intercepting its growth. In a landscape analysis of 1024 lung adenocarcinomas (LUAD) with deep whole-genome sequencing integrated with multiomic data, we identified 542 LUAD that displayed diverse clonal architecture. In this group, we observed an interplay between mobile elements, endogenous and exogenous mutational processes, distinct driver genes, and epidemiological features. Our results revealed divergent evolutionary trajectories based on tobacco smoking exposure, ancestry, and sex. LUAD from smokers showed an abundance of tobacco-related C:G>A:T driver mutations in KRAS plus short subclonal diversification. LUAD in never smokers showed early occurrence of copy number alterations and EGFR mutations associated with SBS5 and SBS40a mutational signatures. Tumors harboring EGFR mutations exhibited long latency, particularly in females of European-ancestry (EU_N). In EU_N, EGFR mutations preceded the occurrence of other driver genes, including TP53 and RBM10. Tumors from Asian never smokers showed a short clonal evolution and presented with heterogeneous repetitive patterns for the inferred mutational order. Importantly, we found that the mutational signature ID2 is a marker of a previously unrecognized mechanism for LUAD evolution. Tumors with ID2 showed short latency and high L1 retrotransposon activity linked to L1 promoter demethylation. These tumors exhibited an aggressive phenotype, characterized by increased genomic instability, elevated hypoxia scores, low burden of neoantigens, propensity to develop metastasis, and poor overall survival. Re-activated L1 retrotransposition-induced mutagenesis can contribute to the origin of the mutational signature ID2, including through the regulation of the transcriptional factor ZNF695 , a member of the KZFP family. The complex nature of LUAD evolution creates both challenges and opportunities for screening and treatment plans.
Novel Benchmark for Adult-to-Adult Living-donor Liver Transplantation
Li, Zhihao , Gunasekaran, Vasanthakumar , Chen, Itsuko Chih-Yi, Marquez, Kris Ann Hervera , Hsu, Shih Chao, Kirimker, Elvan Onur, Akamatsu, Nobuhisa , Shaked, Oren , Genedy, Lara, Dutkowski, Philipp , Boehnert, Markus , Mathur, Abhisek, Emond, Jean C. , Testa, Giuliano , Olthoff, Kim M. , Rosen, Charles B. , Taner, Timuçin , Lo, Chung Mau , Cattral, Mark S. , Jeng, Long Bin, Bröering, Dieter C. , Chen, Chao‐Long, Suk, Kyung-Suh, Rela, Mohamed , Clavien, Pierre‐Alain , Hsu, Shih-Chao , Li, Zhihao , Akamatsu, Nobuhisa , Rammohan, Ashwin , Hong, Su young , Chen, Itsuko Chih-Yi, Kim, Jong Man , Kirimker, Elvan Onur, Finotti, Michele , Yeow, Marcus , Nadalin, Silvio , Polak, Wojciech G. , Bonney, Glenn Kunnath , Mathur, Abhishek , Samstein, Benjamin , Heimbach, Julie K. , Wong, Tiffany , Hasegawa, Kiyoshi , Balci, Deniz , Sapisochín, Gonzalo , Selzner, Nazia , Jeng, Long-Bin , Joh, Jae-Won , Suk, Kyung-Suh

Mayo Clinic

Annals of Surgery | July 21, 2023 | Volume: 278 | Issue: 5 | Pages: 798-806

10.1097/sla.0000000000006038 | PMID 37477016 Get It

Objective: To define benchmark values for adult-to-adult living-donor liver transplantation (LDLT). Background: LDLT utilizes living-donor hemiliver grafts to expand the donor pool and reduce waitlist mortality. Although references have been established for donor hepatectomy, no such information exists for recipients to enable conclusive quality and comparative assessments. Methods: Patients undergoing LDLT were analyzed in 15 high-volume centers (≥10 cases/year) from 3 continents over 5 years (2016–2020), with a minimum follow-up of 1 year. Benchmark criteria included a Model for End-stage Liver Disease ≤20, no portal vein thrombosis, no previous major abdominal surgery, no renal replacement therapy, no acute liver failure, and no intensive care unit admission. Benchmark cutoffs were derived from the 75th percentile of all centers’ medians. Results: Of 3636 patients, 1864 (51%) qualified as benchmark cases. Benchmark cutoffs, including posttransplant dialysis (≤4%), primary nonfunction (≤0.9%), nonanastomotic strictures (≤0.2%), graft loss (≤7.7%), and redo-liver transplantation (LT) (≤3.6%), at 1-year were below the deceased donor LT benchmarks. Bile leak (≤12.4%), hepatic artery thrombosis (≤5.1%), and Comprehensive Complication Index (CCI ® ) (≤56) were above the deceased donor LT benchmarks, whereas mortality (≤9.1%) was comparable. The right hemiliver graft, compared with the left, was associated with a lower CCI ® score (34 vs 21, P < 0.001). Preservation of the middle hepatic vein with the right hemiliver graft had no impact neither on the recipient nor on the donor outcome. Asian centers outperformed other centers with CCI ® score (21 vs 47, P < 0.001), graft loss (3.0% vs 6.5%, P = 0.002), and redo-LT rates (1.0% vs 2.5%, P = 0.029). In contrast, non-benchmark low-volume centers displayed inferior outcomes, such as bile leak (15.2%), hepatic artery thrombosis (15.2%), or redo-LT (6.5%). Conclusions: Benchmark LDLT offers a valuable alternative to reduce waitlist mortality. Exchange of expertise, public awareness, and centralization policy are, however, mandatory to achieve benchmark outcomes worldwide.
Abstract 14735: Carotid Artery Stenting and Carotid Endarterectomy are Comparable Among Medicare Beneficiaries Treated in Routine Clinical Practice
Jalbert, Jessica J. , Nguyen, Louis L. , Gerhard‐Herman, Marie , Williams, Lauren , Chen, Chih‐Ying , Liu, Jun , Rothman, Andrew, Seeger, John D. , Benenati, James F., Schneider, Peter A. , Brott, Thomas G. , Tsai, Thomas T., Setoguchi, Soko , Kumamaru, Hiraku , Jaff, Michael R. , Aronow, Herbert D. , Johnston, Joseph A. , White, Christopher J.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 130 | Issue: suppl_2 | Pages: No page available

10.1161/circ.130.suppl_2.14735 Get It

Introduction: The relative performance of carotid artery stenting (CAS) and carotid endarterectomy (CEA) among Medicare beneficiaries in routine clinical practice has not been established. Objective: To compare the performance of CAS relative to CEA among Medicare beneficiaries. Methods: We linked Medicare data (2000-2009) to the Society for Vascular Surgery’s Vascular Registry (SVS-VR; 2005-2008) and to the NCDR® Carotid Artery Revascularization and Endarterectomy Registry (CARE; 2006-2008/9). Medicare patients aged ≥66 years undergoing CAS or CEA were followed from the procedure date for the outcomes of death, stroke/transient ischemic attack (TIA), peri-procedural myocardial infarction (MI) or a composite endpoint for these outcomes. We derived high-dimensional propensity scores using registry and Medicare data to control for patient-level factors and adjusted for provider-level factors including past-year CAS/CEA physician and hospital volume, hospital ownership, teaching affiliation, and hospital size in a Cox regression model comparing CAS to CEA. Results: Among 5,254 SVS-VR (1,999 CAS and 3,255 CEA) and 4,055 CARE (2,824 CAS and 1,231 CEA) patients, CAS patients were more often at higher surgical risk (SVS-VR: 96.7% vs. 44.5%; CARE: 71.3% vs. 44.7%) and had a higher comorbidity burden. Crude outcome risks for death and stroke/TIA were lower for CEA. Adjusting for patient-level factors drove estimates downwards for CAS relative to CEA but only after further adjustment for provider-level factors did the performance of CAS and CEA become comparable on all outcomes (figure 1). Conclusion: Performance of CAS and CEA among Medicare beneficiaries was comparable after accounting for patient- and provider-level factors, which is consistent with landmark trials. Further studies are needed to understand the role of heterogeneity in provider-level characteristics.
Natural History of Prostatism: Urinary Flow Rates in A Community-Based Study
Panser, Laurel A., Oesterling, Joseph E., Arrighi, H. Michael, Guess, H. A., Lieber, Michael M., Girman, Cynthia J. , Chute, Christopher G. , Barrett, David M. , Chen, Chu‐Chih

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 150 | Issue: 3 | Pages: 887-892

10.1016/s0022-5347(17)35640-9 | PMID 7688433 Get It

Hirsutinolide Series Inhibit Stat3 Activity, Alter GCN1, MAP1B, Hsp105, G6PD, Vimentin, TrxR1, and Importin α-2 Expression, and Induce Antitumor Effects against Human Glioma
Miklóssy, Gabriella, Zhang, Mingming , Chen, Chih-Hong, Hilliard, Tyvette S. , Paladino, David, Choi, Justin Chin-Bong , Kawakami, Joel K., Wongwiwatthananukit, Supakit , Chen, Yuan , Sun, Dianqing , Chang, Leng Chee , Turkson, James , Youn, Ui Joung , Yue, Peibin , Li, Yifei , Sarkaria, Jann N.

Mayo Clinic

Journal of Medicinal Chemistry | September 2, 2015 | Volume: 58 | Issue: 19 | Pages: 7734-7748

10.1021/acs.jmedchem.5b00686 | PMID 26331426 Get It